Introduction
Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed in the Russian neuropeptide research community in the 1990s as a stabilized synthetic analog of the natural immunoregulatory tetrapeptide Tuftsin. The "Sel-" portion of the name was chosen by the developers to evoke the conceptual lineage of the molecule from the Tuftsin research tradition, and the C-terminal Pro-Gly-Pro extension reflects the same stability-design strategy that the same Russian research community used in developing the related neuropeptide Semax. Selank is one of the better-known products of the Russian neuropeptide tradition and has been registered as a pharmaceutical product in the Russian Federation for anxiety-related indications, though it has not been advanced through the conventional pharmaceutical approval pathways in the United States, European Union, or other major international regulatory jurisdictions.
The scientific interest in Selank sits at the intersection of Tuftsin biology, anxiety-related neuropeptide pharmacology, GABAergic signaling research, and broader research on immunoregulatory peptides with central nervous system activity. Tuftsin itself — the natural tetrapeptide Thr-Lys-Pro-Arg derived from the Fc region of immunoglobulin G — has a long research history as an immunoregulatory peptide with effects on phagocyte function and on various aspects of the innate immune response. The Russian neuropeptide research community, building on the Tuftsin framework and on the broader conceptual interest in immunoregulatory peptides with CNS activity, developed Selank as a stabilized synthetic analog intended to retain the Tuftsin-derived activities while providing improved stability and possibly extending the activity profile into anxiety-related and other CNS-relevant domains.
The published research conversation around Selank has included reports of effects on GABAergic neurotransmission, on the expression of various neurotransmitter receptor genes, on neuropeptide Y and other downstream neuropeptide systems, on anxiety-related endpoints in animal models, on immunoregulatory endpoints connected to the Tuftsin lineage, and on broader behavioral and cognitive endpoints in research models. The compound is registered for clinical use in the Russian Federation in anxiety-related indications, with the supporting clinical-research evidence generated primarily within the Russian regulatory and research ecosystem. The international research-peptide market includes Selank as a tool for laboratory-research investigation of the broader Tuftsin and neuropeptide research conversations.
This page is a plain-English educational reference for readers who want to understand what Selank actually is, where it came from, what its proposed mechanisms in the published research are, and where it sits in the broader research peptide landscape. It is not a medical guide, it does not describe a treatment for any individual, and it makes no claims about anxiety, cognitive, or immunoregulatory effects in people who purchase the compound for laboratory use. Selank supplied as a research peptide is intended for laboratory and analytical purposes only, and the entire discussion below is framed within that context.
Throughout the page, terms that recur in Selank research — Tuftsin, Pro-Gly-Pro, GABAergic, neuropeptide Y, anxiolytic — are defined as they come up, and the glossary at the end collects them. The FAQ addresses the questions that most often arise about Selank specifically and about the broader Russian neuropeptide research conversation.
What Is Selank?
Selank is a synthetic linear heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and a molecular mass of approximately 751 daltons in the free-acid form. The peptide has no disulfide bonds, no cyclization, and no covalent modifications beyond the standard amide-bond backbone, but its design reflects a deliberate combination of the natural Tuftsin sequence with a modified C-terminal extension.
The first four residues — Thr-Lys-Pro-Arg — correspond exactly to the natural Tuftsin tetrapeptide, an immunoregulatory peptide that occurs as a sequence within the CH2 domain of the heavy chain of immunoglobulin G (specifically, residues 289-292 of the IgG heavy chain). Tuftsin is released from IgG by proteolytic cleavage and acts on phagocytic cells (monocytes, macrophages, neutrophils) to modulate phagocytic function, chemotaxis, and various other aspects of innate immunity. The Tuftsin sequence was originally identified and characterized in the 1970s by Najjar and colleagues, and the tetrapeptide has been a subject of substantial immunology research since then.
The remaining three residues of Selank — Pro-Gly-Pro — are a deliberate C-terminal extension. The Pro-Gly-Pro motif is the same stability-design feature used in Semax (the companion Russian neuropeptide that derives from ACTH(4-10) rather than from Tuftsin); the motif confers substantial protease resistance and improves the biological half-life of the molecule relative to the unmodified Tuftsin tetrapeptide. The design rationale combined the Tuftsin starting sequence with the C-terminal stability extension to produce a stable, well-characterized synthetic neuropeptide suitable for systematic research and clinical-research investigation.
The proposed mechanism of Selank in the published research is multifaceted. The Tuftsin core sequence retains some level of the immunoregulatory activity of natural Tuftsin, with effects on phagocyte function and on various aspects of innate immunity reported in some research contexts. The broader CNS effects characterized in the Selank literature — including effects on anxiety-related endpoints, on GABAergic signaling, on neuropeptide Y expression, and on broader behavioral endpoints — are not all attributable to the Tuftsin sequence per se and may reflect distinct mechanisms specific to the modified molecule. The detailed proximal molecular targets responsible for the CNS effects have not been fully resolved at the level of specific receptor binding and signaling pathway activation; the molecular pharmacology of Selank is more characterized by its functional endpoints in the published research than by a fully mapped molecular target profile.
It is worth being specific about what Selank is not. It is not Tuftsin itself — Tuftsin is the unmodified natural tetrapeptide Thr-Lys-Pro-Arg with the much shorter biological half-life of an unprotected tetrapeptide, and Selank is the modified seven-amino-acid stabilized analog. It is not Semax — the two Russian neuropeptides share the C-terminal Pro-Gly-Pro stabilization but have entirely different N-terminal sequences and different proposed mechanisms, with Selank deriving from Tuftsin and Semax deriving from ACTH(4-10). It is not a benzodiazepine or any other small-molecule anxiolytic; it is a peptide with proposed mechanisms distinct from the GABA-A receptor positive modulation that characterizes the benzodiazepine class. And it is not an approved medicine in major international regulatory jurisdictions outside the Russian Federation regulatory framework.
History and Development
The history of Selank begins with the broader history of Tuftsin, which dates to the 1970s. Tuftsin was identified and named by Victor Najjar and colleagues at Tufts University (hence the name) in the early 1970s as a tetrapeptide sequence within the CH2 domain of the heavy chain of immunoglobulin G that, when released by proteolytic cleavage, has immunoregulatory activity on phagocytic cells. The original work characterized Tuftsin's effects on phagocyte function, on chemotaxis, on respiratory burst activity, and on various other aspects of innate immune response. The natural occurrence of the Tuftsin sequence within IgG provided a conceptual framework in which the tetrapeptide could be understood as an endogenous immunoregulatory signal released from the major immunoglobulin scaffold.
Through the 1970s and 1980s, Tuftsin research expanded across multiple laboratories internationally, with characterization of the molecular mechanisms (proposed involvement of specific Tuftsin receptors on phagocytic cells), of the structure-activity relationships (with various Tuftsin analogs designed and tested), and of the broader immunology context. The work established Tuftsin as a well-characterized immunoregulatory peptide with substantive research support. The natural tetrapeptide, however, is rapidly degraded by aminopeptidases and other proteases, with a very short biological half-life that limited its practical utility as a research tool and as a candidate clinical compound.
The Russian neuropeptide research community, with the M. M. Shemyakin and Y. A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences as a central site, developed Selank in the 1990s as a stabilized synthetic analog combining the Tuftsin starting sequence with the C-terminal Pro-Gly-Pro extension. The design was part of the same research program that produced the related Russian neuropeptide Semax (a stabilized ACTH(4-10) analog with the same C-terminal motif). The shared Pro-Gly-Pro stabilization strategy reflects the consistent design framework that this research community applied to multiple natural peptide starting points to produce stable synthetic analogs suitable for systematic research and clinical-research investigation.
Through the 1990s and 2000s, Selank was advanced through Russian laboratory and clinical-research studies. The research focused on anxiety-related endpoints, on GABAergic signaling effects, on neuropeptide Y and other downstream neuropeptide systems, on immunoregulatory endpoints connected to the Tuftsin lineage, and on broader behavioral and cognitive endpoints. The compound was registered as a pharmaceutical product in the Russian Federation for use in anxiety-related indications, with the registration based on Russian clinical-research evidence within the Russian regulatory framework. The Russian product is supplied as an intranasal solution, reflecting the same formulation strategy used for the related Semax product and the broader Russian preference for intranasal peptide formulation in CNS-targeted research peptides.
International engagement with the Selank literature has occurred at meaningful levels through publications in mainstream peptide and neuroscience journals through the 2000s and 2010s. The international research has supported some of the key Russian findings — particularly the anxiety-related behavioral endpoints in animal models and some aspects of the GABAergic signaling characterization — while leaving various detailed mechanistic questions open. The compound has not been advanced through the conventional pharmaceutical approval pathways outside the Russian Federation and remains available in the international research peptide market for laboratory and analytical use rather than as an approved medicine in other regulatory jurisdictions.
Important milestones in the Selank literature include the Najjar identification of Tuftsin in the early 1970s, the substantial Tuftsin immunology research of the 1970s-1980s establishing the natural-peptide framework, the design and characterization of Selank by the Russian neuropeptide research community in the 1990s, the Russian clinical-research and pharmaceutical registration in the 1990s-2000s, and the continuing international research presence of the compound through the 2010s and 2020s.
Understanding the Science
The science of Selank is anchored in three connected areas: Tuftsin biology and broader immunoregulatory peptide research, the molecular pharmacology characterized in the Selank-specific literature, and the broader landscape of stabilized natural-peptide analogs in CNS and immunology research.
Tuftsin biology
Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that occurs as a sequence within the CH2 domain of the heavy chain of immunoglobulin G. The sequence is released from IgG by proteolytic cleavage and has been characterized as an endogenous immunoregulatory peptide acting on phagocytic cells. Effects described in the published research include enhancement of phagocytic activity, stimulation of chemotaxis, modulation of respiratory burst activity, and broader effects on innate immune function. The proposed mechanism involves binding to specific Tuftsin receptors on phagocytic cells, though the molecular identity of the Tuftsin receptor has been a subject of ongoing characterization in the immunology literature. Selank retains the Tuftsin sequence as its N-terminal core and may retain some of the Tuftsin-attributable immunoregulatory activity.
Selank's CNS pharmacology
The CNS effects characterized in the Selank literature go beyond what would be expected purely from the Tuftsin immunoregulatory framework. Published research has reported effects on GABAergic neurotransmission — including effects on GABA-A and GABA-B receptor function in various brain regions — that contribute to the anxiety-related behavioral endpoints characterized in animal models. The molecular basis of the GABAergic effects is not fully resolved at the level of direct binding to GABA receptors; the effects may reflect indirect modulation through neuropeptide-Y-related signaling or through other intermediate pathways. The compound has also been reported to affect serotonergic and dopaminergic signaling in some research contexts, contributing to the broader behavioral and cognitive endpoint profile.
Neuropeptide Y and downstream neuropeptide systems
One of the more characteristic findings in the Selank literature is the report of effects on neuropeptide Y (NPY) expression in various brain regions. NPY is a 36-amino-acid neuropeptide widely expressed in the CNS with effects on feeding, anxiety, stress responses, and various other functions. Selank-induced upregulation of NPY in regions including hippocampus has been proposed as one of the mechanisms through which Selank's anxiety-related behavioral effects arise, given the well-established role of NPY in anxiety and stress biology. The connection between Selank administration and downstream NPY effects has been documented across multiple studies, though the proximal molecular target connecting Selank binding to NPY gene transcription has not been fully resolved.
Anxiety-related behavioral endpoints
Animal-model studies have characterized Selank's effects on anxiety-related behavioral endpoints — including elevated plus maze performance, open field activity, light-dark box behavior, and other standard rodent anxiety paradigms. Reported effects include anxiolytic-like behavior in these paradigms across the dose ranges that have been studied. The behavioral findings have been part of the basis for the Russian clinical-research use of Selank in anxiety-related indications.
Immunoregulatory effects
Reflecting the Tuftsin lineage, some published Selank research has characterized effects on immune function — including effects on cytokine expression, on T-cell and B-cell function, and on broader immunoregulatory endpoints. The research connects to the broader immunology context in which Tuftsin and Tuftsin analogs have been studied for decades. The relationship between the immunoregulatory effects of Selank and the CNS effects is one of the more interesting conceptual questions in the literature, with the broader research framework of immune-CNS interactions providing context for the dual-domain activity profile.
Intranasal pharmacokinetics
The Russian clinical product is formulated as an intranasal solution, taking advantage of the relatively rapid absorption of peptides across the nasal mucosa and the proposed access to the CNS through the olfactory and trigeminal pathways. The intranasal route bypasses the rapid plasma proteolysis that affects orally or intravenously administered peptides. The pharmacokinetic profile of Selank has been characterized to varying degrees of detail in the published research; the molecule has a short plasma half-life characteristic of small peptides without major stability modifications beyond the Pro-Gly-Pro extension.
- Selank is a synthetic seven-amino-acid peptide combining the natural Tuftsin sequence with a C-terminal Pro-Gly-Pro stabilization extension.
- Published research includes effects on GABAergic neurotransmission, neuropeptide Y expression, and anxiety-related behavioral endpoints in animal models.
- Some immunoregulatory effects reflect the Tuftsin lineage, connecting to broader research on innate immune peptide signaling.
- Registered as a pharmaceutical product in the Russian Federation for anxiety-related indications; not approved in major international regulatory jurisdictions.
- Available internationally as a research peptide for laboratory and analytical investigation.
Structural Characteristics
Structurally, Selank is a linear heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and a molecular mass of approximately 751 daltons in the free-acid form. The peptide has no disulfide bonds and no cyclization, and the only "design modifications" relative to the natural Tuftsin starting sequence are the addition of the C-terminal Pro-Gly-Pro extension.
The first four residues — Thr-Lys-Pro-Arg — correspond exactly to natural Tuftsin. The threonine at position 1 provides the N-terminal anchor; the lysine at position 2 contributes positive charge from the side-chain amine; the proline at position 3 introduces conformational restriction; and the arginine at position 4 contributes additional positive charge from the guanidinium side chain. The overall charge of this N-terminal tetrapeptide segment is strongly basic at physiological pH, reflecting the lysine and arginine side chains and the protonated N-terminal amine.
The C-terminal Pro-Gly-Pro motif is the design-distinctive feature shared with Semax. The two consecutive proline residues (at positions 5 and 7) with the intervening glycine confer substantial protease resistance, particularly against the C-terminal aminopeptidases and carboxypeptidases that would otherwise rapidly degrade the C-terminal end of an unmodified Tuftsin-derived peptide. The Pro-Gly-Pro motif specifically retains the natural Tuftsin tetrapeptide at the N-terminus (preserving its receptor-binding-relevant character) while providing a stabilized C-terminal extension that is not present in any natural peptide of clear comparable structure.
Three of the seven residues of Selank are prolines, giving the molecule a substantial conformational restriction overall. The proline residues at positions 3, 5, and 7 each introduce backbone constraints that limit the overall conformational flexibility of the peptide. This high proline content is one of the distinctive structural features of Selank and contributes both to the stability and to the specific conformational properties of the molecule in aqueous solution.
Stability characteristics of Selank are favorable enough for practical research use. The Pro-Gly-Pro C-terminus provides significantly better protease resistance than the natural Tuftsin tetrapeptide. Lyophilized material stored sealed at deep-freeze temperatures away from light is generally considered stable for extended periods. The peptide has no methionine residues to oxidize and no cysteines for disulfide concerns, simplifying storage relative to peptides with those residues.
Research-grade Selank is produced through standard solid-phase peptide synthesis using Fmoc protecting-group chemistry. The proline-rich sequence requires some attention to coupling efficiency at the multiple proline-containing junctions, but synthesis presents no insurmountable challenges. The crude peptide is purified by reversed-phase HPLC and characterized by mass spectrometry. A Certificate of Analysis for research-grade Selank typically reports the sequence, the measured molecular mass, the HPLC purity percentage, and the residual moisture content of the lyophilized powder. The lysine and arginine residues contribute multiple basic functional groups, so the peptide is typically supplied as the multi-acetate or multi-trifluoroacetate salt depending on the purification protocol.
Areas of Scientific Interest
Selank has been used as a research tool across a focused set of themes connected to Tuftsin biology, anxiety-related neuropeptide pharmacology, GABAergic signaling, immunoregulatory peptide research, and broader behavioral and cognitive neuroscience. None of the areas described below represents a therapeutic use of Selank in individuals outside the Russian regulatory framework, and none should be read as suggesting clinical benefit in other contexts. They are research directions where the compound has been useful as a defined experimental probe.
Anxiety-related behavioral research
The most prominent research use of Selank is in animal-model studies of anxiety-related behavioral endpoints. Standard rodent paradigms including elevated plus maze, open field, light-dark box, and social interaction tests have been used to characterize the behavioral profile of Selank across dose ranges and time courses. The findings have been the basis for the Russian clinical-research use of Selank in anxiety-related indications and continue to be a major area of Selank research internationally.
GABAergic signaling research
Research on Selank's effects on GABAergic neurotransmission has examined functional effects on GABA-A and GABA-B receptor activity, gene-expression effects on GABA receptor subunit transcription, and broader effects on inhibitory signaling in various brain regions. The research connects to the broader interest in GABAergic modulation in anxiety biology and provides one of the proposed mechanistic angles on the anxiety-related behavioral effects of the compound.
Neuropeptide Y research
The reported effects of Selank on neuropeptide Y expression in hippocampus and other brain regions have made the compound a useful tool in research on NPY biology and on the broader role of NPY in anxiety, stress, and feeding regulation. The connection between Selank administration and downstream NPY effects has been one of the more frequently studied molecular endpoints in the Selank literature.
Tuftsin biology and immunoregulatory research
Reflecting the Tuftsin lineage, Selank has appeared in research on immunoregulatory peptide signaling — including studies of phagocyte function, cytokine expression, T-cell and B-cell function, and broader immune endpoints. The research connects to the long-standing Tuftsin immunology literature and provides a tool for studying the dual-domain (CNS and immune) activity profile that the compound exhibits.
Cognitive and behavioral neuroscience
Beyond the anxiety-specific behavioral research, Selank has been used in broader cognitive and behavioral neuroscience studies — including learning and memory tasks, attention paradigms, and other behavioral assays relevant to cognitive function. The research builds on the broader interest in peptide modulators of cognition and provides comparative context for the related Russian neuropeptide Semax.
Intranasal peptide delivery research
The Russian product formulation of Selank as an intranasal solution has made the compound a useful subject in research on intranasal peptide delivery, including studies of nasal mucosal absorption, of access to the CNS through olfactory and trigeminal pathways, and of comparative pharmacokinetic profiles between intranasal and other routes of administration. This research connects to the broader field of intranasal peptide therapeutics and to the specific question of how peptide formulation affects CNS-targeted activity.
Comparative neuropeptide research
Selank appears in comparative studies alongside other neuropeptides — including the related Russian neuropeptide Semax, the natural Tuftsin tetrapeptide, various other immunoregulatory peptides, and unrelated CNS-targeted peptides. The comparative research informs understanding of structure-function relationships in the broader stabilized-peptide analog space and of the comparative pharmacology of different design strategies in peptide medicinal chemistry.
- Anxiety-related behavioral research in animal models
- GABAergic neurotransmission and inhibitory signaling research
- Neuropeptide Y expression and biology research
- Tuftsin biology and immunoregulatory peptide signaling
- Cognitive and behavioral neuroscience studies
- Intranasal peptide delivery research
- Comparative neuropeptide pharmacology
Comparison With Related Compounds
Selank sits in a family of Russian neuropeptides and Tuftsin-related compounds, and is best understood relative to several distinct categories of compound.
The closest comparison is with natural Tuftsin — the unmodified tetrapeptide Thr-Lys-Pro-Arg that occurs naturally in IgG and serves as the conceptual starting point for the Selank design. Natural Tuftsin has substantial immunoregulatory activity but is rapidly degraded by aminopeptidases and other proteases, with a very short biological half-life that limited its practical utility. Selank retains the Tuftsin tetrapeptide as its N-terminal core and adds the stabilizing C-terminal Pro-Gly-Pro extension. The comparison illustrates the design trade-offs between fidelity to the natural peptide and stability for systematic research and clinical use.
A second comparison is with Semax, the companion Russian neuropeptide developed in the same research community using the same C-terminal Pro-Gly-Pro stabilization strategy. Semax derives from ACTH(4-10) rather than from Tuftsin and has an entirely different N-terminal sequence (Met-Glu-His-Phe rather than Thr-Lys-Pro-Arg), a different proposed mechanism (involving the melanocortin core sequence and BDNF/cholinergic effects rather than the Tuftsin/GABAergic/NPY profile of Selank), and a different Russian regulatory indication (neuroprotection in ischemic stroke and certain cognitive disorders rather than anxiety). The two compounds are often discussed together because of their shared Russian research lineage and the common stabilization strategy but should not be conflated as alternative versions of the same compound.
Selank is also sometimes compared with benzodiazepines and other small-molecule anxiolytics. These small molecules act primarily as positive modulators of the GABA-A receptor (the benzodiazepine class) or through other defined molecular mechanisms specific to each compound class. Selank's proposed mechanism involves indirect modulation of GABAergic signaling and downstream effects on neuropeptide Y rather than direct GABA-A receptor positive modulation, making it pharmacologically distinct from the benzodiazepine class even when discussed in the context of anxiety-related research.
In the broader Russian and international neuropeptide research landscape, Selank is part of a family of stabilized natural-peptide analogs that includes Semax, various other Russian neuropeptides (some with the same Pro-Gly-Pro stabilization, others with different design strategies), and the broader international peptide-medicinal-chemistry tradition. Selank's specific identity as a stabilized Tuftsin analog with documented anxiety-related and GABAergic effects distinguishes it within this broader landscape.
| Compound | Classification | Distinguishing feature |
|---|---|---|
| Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) | Synthetic stabilized Tuftsin analog (heptapeptide) | Tuftsin N-terminus with Pro-Gly-Pro stabilization; effects on GABAergic signaling, NPY, and anxiety-related behavior in research. |
| Tuftsin (natural Thr-Lys-Pro-Arg) | Natural immunoregulatory tetrapeptide from IgG | Unmodified natural sequence; rapidly degraded with short biological half-life; conceptual starting point for Selank design. |
| Semax | Companion Russian neuropeptide (stabilized ACTH(4-10) analog) | Same Pro-Gly-Pro stabilization strategy but different N-terminal sequence (ACTH-derived); different proposed mechanism and Russian clinical indication. |
| Benzodiazepines (e.g., diazepam) | Small-molecule GABA-A positive allosteric modulators | Direct GABA-A receptor modulation; entirely different chemical class and mechanism from Selank's peptide profile. |
| Oxytocin | Natural nonapeptide hormone | Different sequence, structure, and proposed mechanism; sometimes discussed in similar CNS contexts but pharmacologically distinct from Selank. |
| Tuftsin analogs (various) | Family of synthetic Tuftsin sequence variants | Various modifications to the Tuftsin sequence developed across multiple research laboratories; Selank is one specific design within this broader family. |
Scientific Research Overview
The Selank literature gives a particular impression: a stabilized synthetic analog of the natural immunoregulatory tetrapeptide Tuftsin, developed in the Russian neuropeptide research community in the 1990s with the same C-terminal Pro-Gly-Pro stabilization used in the companion neuropeptide Semax, advanced through Russian clinical-research and registered as a pharmaceutical product for anxiety-related indications in the Russian Federation, and present in the broader international research-peptide market and the international neuropeptide research literature as a tool for laboratory-research investigation of Tuftsin biology, anxiety-related neuropeptide pharmacology, and immune-CNS interactions. The compound's place in the broader peptide research landscape is distinctive: it bridges the immunology Tuftsin tradition with the CNS-targeted Russian neuropeptide design framework, producing a molecule with dual-domain activity that has supported both immunoregulatory and anxiety-related research lines.
The conceptual foundation of Selank is reasonably well grounded. The Tuftsin starting sequence has substantial supporting research dating to the 1970s in the immunology context. The Pro-Gly-Pro stabilization strategy has been demonstrated to confer protease resistance in multiple compounds including the related Semax. The behavioral effects in anxiety-related animal-model paradigms have been characterized across multiple studies. The proposed mechanism involving downstream effects on neuropeptide Y expression and GABAergic signaling has substantial supporting research, though the proximal molecular targets responsible for those effects are not fully resolved at the level of specific receptor binding and signaling pathway activation.
The clinical-research arc of Selank is substantive but largely confined to the Russian regulatory environment, similar to the Semax situation. The compound is registered in the Russian Federation for anxiety-related indications, with supporting clinical-research evidence generated primarily within the Russian research and regulatory ecosystem. The compound has not been advanced through the conventional pharmaceutical approval pathways in the U.S., EU, or other major international jurisdictions, and the international scientific community's engagement with the clinical-research literature has been at a level somewhat below the engagement with comparable compounds that had broader international development histories.
Independent replication and characterization of Selank findings outside the Russian research community has occurred to a meaningful degree but is less comprehensive than for many compounds with broader international development. The anxiety-related behavioral endpoints, the GABAergic signaling effects, and the neuropeptide Y expression effects have all been examined by international research groups at various points, with the overall picture broadly supporting the Russian findings while leaving various detailed mechanistic questions open.
Methodologically, Selank research has used cell-culture systems (particularly for the molecular pharmacology characterization), animal models (rodent anxiety, behavioral, and cognitive paradigms predominantly), and human clinical-research studies in the Russian regulatory context. The pharmacokinetic profile is characterized to a reasonable degree of detail, particularly for the intranasal route used in the Russian product. The pharmacodynamic profile across the various research endpoints has been documented but with the limitations that the relatively concentrated Russian research community brings.
Open questions in the Selank field include the proximal molecular targets responsible for the GABAergic and NPY effects, the relative contributions of Tuftsin-attributable activity versus Selank-specific activity to the observed effects, the comparative biology with other stabilized Tuftsin analogs and with related neuropeptides, and the translation of Russian clinical-research findings to controlled-study contexts in other regulatory environments.
For students, researchers, and curious readers approaching Selank for the first time, the most accurate framing is that of a thoughtfully designed stabilized Tuftsin analog with a substantial research literature anchored in the Russian neuropeptide research community, with effects on anxiety-related behavior, GABAergic signaling, and neuropeptide Y expression in animal-model contexts, and with a Russian Federation pharmaceutical registration that does not extend to other major regulatory jurisdictions. The compound is supplied for laboratory and analytical use only as a research peptide in the international market, and educational discussion of it needs to stay within that framing rather than drift into therapeutic recommendations or claims about effects in people who purchase the compound for research.
Frequently Asked Questions
Q.What is Selank?
Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed in the Russian neuropeptide research community in the 1990s as a stabilized analog of the natural immunoregulatory tetrapeptide Tuftsin. The first four residues are identical to Tuftsin (preserving the Tuftsin starting sequence), and the C-terminal Pro-Gly-Pro extension is a design modification that confers protease resistance and improves stability relative to the natural Tuftsin tetrapeptide. Selank is registered as a pharmaceutical product in the Russian Federation for anxiety-related indications and is available internationally as a research peptide for laboratory and analytical use.
Q.What is Tuftsin?
Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that occurs as a sequence within the CH2 domain of the heavy chain of immunoglobulin G. The sequence is released from IgG by proteolytic cleavage and acts as an immunoregulatory peptide on phagocytic cells (monocytes, macrophages, neutrophils), modulating phagocytic function, chemotaxis, and various other aspects of innate immune response. The peptide was originally identified and characterized by Victor Najjar and colleagues at Tufts University (giving rise to the name) in the early 1970s. Selank uses the Tuftsin tetrapeptide as its N-terminal sequence with a C-terminal stabilization extension.
Q.How does Selank work mechanistically?
The published research describes Selank's mechanism as involving effects on GABAergic neurotransmission (with effects on GABA-A and GABA-B receptor function in various brain regions), effects on neuropeptide Y (NPY) expression in regions including hippocampus, effects on serotonergic and dopaminergic signaling in some contexts, and some retention of the Tuftsin-attributable immunoregulatory activity on phagocytic cells. The detailed proximal molecular targets responsible for the various effects have not been fully resolved at the level of specific receptor binding and signaling pathway activation; the molecular pharmacology of Selank is characterized more by its functional endpoints than by a fully mapped molecular target profile.
Q.How is Selank different from Semax?
Both are Russian neuropeptides developed in the same research community using the same C-terminal Pro-Gly-Pro stabilization strategy, but they have entirely different N-terminal sequences and different conceptual lineages. Selank's N-terminus is the Tuftsin tetrapeptide (Thr-Lys-Pro-Arg), derived from the immunoregulatory peptide research tradition. Semax's N-terminus is the melanocortin core sequence (Met-Glu-His-Phe), derived from ACTH(4-10) and the broader 'behavioral fragment' tradition. The two compounds have different proposed mechanisms, different research literature footprints, and different Russian regulatory indications — Selank for anxiety, Semax for ischemic stroke and certain cognitive disorders.
Q.Is Selank an anxiolytic?
Within the Russian regulatory framework, Selank is registered for anxiety-related indications based on Russian clinical-research evidence. Animal-model studies have characterized anxiolytic-like behavior in standard rodent paradigms including elevated plus maze, open field, and light-dark box. The proposed mechanism involves indirect modulation of GABAergic signaling and downstream effects on neuropeptide Y, distinct from the direct GABA-A positive allosteric modulation that characterizes the benzodiazepine class. In the broader international regulatory context, Selank is not approved as an anxiolytic medicine and is available as a research peptide for laboratory and analytical investigation only. Educational discussion of Selank as 'an anxiolytic' should be qualified by these context distinctions.
Q.How is Selank related to neuropeptide Y?
One of the more characteristic findings in the Selank literature is the report of effects on neuropeptide Y (NPY) expression in various brain regions, particularly hippocampus. NPY is a 36-amino-acid neuropeptide widely expressed in the CNS with well-established roles in anxiety, stress, feeding, and various other functions. Selank-induced upregulation of NPY has been proposed as one of the mechanisms through which Selank's anxiety-related behavioral effects arise, given the well-established role of NPY in anxiety biology. The connection between Selank administration and downstream NPY effects has been documented across multiple studies, though the proximal molecular target connecting Selank binding to NPY gene transcription has not been fully resolved.
Q.Is Selank approved as a medicine?
Selank is registered as a pharmaceutical product in the Russian Federation for anxiety-related indications. The supporting clinical-research evidence for the Russian registration was generated primarily within the Russian research and regulatory ecosystem. Selank is not approved as a medicine in the United States, the European Union, Japan, or other major international regulatory jurisdictions. The international research-peptide market includes Selank as a tool for laboratory and analytical research only, not as an approved medicine in those jurisdictions.
Q.What is the Pro-Gly-Pro motif in Selank?
Pro-Gly-Pro is the C-terminal three-residue extension of Selank — proline-glycine-proline — that follows the natural Tuftsin tetrapeptide in the Selank sequence. The motif provides substantial resistance to the aminopeptidases and other proteases that would otherwise rapidly degrade an unmodified Tuftsin-derived peptide. The same Pro-Gly-Pro motif is used in the related Russian neuropeptide Semax, reflecting the consistent stabilization-design strategy that the Russian neuropeptide research community applied to multiple natural peptide starting points. The motif's protease resistance derives from the conformational restriction provided by the proline residues, which makes adjacent peptide bonds less accessible to proteolytic cleavage.
Q.Why is Selank formulated as an intranasal solution?
The intranasal route bypasses the rapid plasma proteolytic degradation that affects orally or intravenously administered peptides and may improve CNS exposure through proposed access via the olfactory and trigeminal pathways from the nasal mucosa. For a peptide like Selank that targets effects in the central nervous system and has a short plasma half-life characteristic of small peptides, intranasal administration is an established formulation strategy. The Russian pharmaceutical product is supplied as an intranasal solution reflecting this design, matching the formulation strategy used for the related Semax product.
Q.Does Selank have immunoregulatory effects?
Yes, reflecting the Tuftsin lineage, some published Selank research has characterized effects on immune function — including effects on cytokine expression, on phagocyte function, on T-cell and B-cell function, and on broader immunoregulatory endpoints. The relationship between the immunoregulatory effects and the CNS effects of Selank is one of the more interesting conceptual questions in the literature, with the broader research framework of immune-CNS interactions providing context for the dual-domain activity profile. The immunoregulatory effects are generally characterized as less prominent than the CNS effects in the Selank-specific research, but the Tuftsin-attributable activity is part of the molecular identity of the compound.
Q.What is the molecular weight of Selank?
The molecular mass of Selank in the free-acid form is approximately 751 daltons. The peptide has no covalent modifications beyond the standard amide-bond backbone, and the seven-residue length with the specific amino acid composition gives the characteristic mass. The basic residues (lysine and arginine) contribute multiple positive charges at physiological pH, so the peptide is typically supplied as a multi-counterion salt depending on the purification protocol. The molecular mass is one of the analytical parameters reported on a Certificate of Analysis for research-grade material, confirmed by mass spectrometry.
Q.How is Selank manufactured?
Research-grade Selank is produced by standard solid-phase peptide synthesis using Fmoc protecting-group chemistry. The proline-rich sequence requires some attention to coupling efficiency at the multiple proline-containing junctions, but synthesis presents no insurmountable challenges. The crude peptide is purified by reversed-phase HPLC and characterized by mass spectrometry. Reputable suppliers report purity in the 98-99% range for research-grade material. The lysine and arginine residues contribute multiple basic side chains, and the peptide is typically supplied as the multi-acetate or multi-trifluoroacetate salt depending on the purification protocol.
Q.Does Selank act on benzodiazepine receptors?
No. Selank's proposed mechanism involves indirect modulation of GABAergic signaling and downstream effects on neuropeptide Y rather than direct binding to the benzodiazepine site on the GABA-A receptor. The benzodiazepine class of small molecules acts as positive allosteric modulators at a specific site on the GABA-A receptor distinct from the GABA binding site. Selank is a peptide with proposed effects that may converge on GABAergic signaling through indirect mechanisms rather than through direct receptor modulation at the benzodiazepine site. The two classes are pharmacologically distinct despite sometimes being discussed in similar anxiety-related research contexts.
Q.What are the reported behavioral effects in animal models?
Animal-model studies have characterized Selank's effects on anxiety-related behavioral endpoints using standard rodent paradigms including elevated plus maze (measuring willingness to enter open arms), open field (measuring exploratory behavior in an unfamiliar environment), light-dark box (measuring time spent in lit versus dark compartments), and social interaction tests. The reported findings include anxiolytic-like behavior in these paradigms across the dose ranges that have been studied. Some studies have also reported effects on learning and memory endpoints and on broader behavioral activity, though the anxiety-related findings are the most prominent.
Q.Who developed Selank?
Selank was developed in the Russian (formerly Soviet) neuropeptide research community in the 1990s, with the M. M. Shemyakin and Y. A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences as a central site for the development work. The development was part of the same broader research program that produced the related Russian neuropeptide Semax (using the same Pro-Gly-Pro stabilization strategy applied to a different natural peptide starting point). The compound was advanced through Russian clinical-research and registered as a Russian pharmaceutical product in the late 1990s and early 2000s.
Q.Is Selank safe?
Safety characterization for Selank exists at multiple levels. The Russian Federation regulatory approval for the clinical pharmaceutical product reflects an evaluation of safety within the Russian regulatory framework. The published research literature reports a generally favorable tolerability profile in the studies that have been conducted. However, the comprehensive safety characterization typical for compounds approved as medicines in the major international regulatory jurisdictions (U.S. FDA, EU EMA) is not available for Selank in those jurisdictions; the compound has not been approved as a medicine in those contexts. The research peptide form discussed on this page is supplied for laboratory and analytical use only.
Q.How does Selank compare to benzodiazepines?
Pharmacologically very different. Benzodiazepines are small molecules that act as positive allosteric modulators of the GABA-A receptor at a specific binding site distinct from the GABA binding site; they produce direct, well-characterized GABA-A receptor potentiation. Selank is a peptide whose proposed mechanism involves indirect modulation of GABAergic signaling and downstream effects on neuropeptide Y rather than direct GABA-A receptor modulation. The two classes have entirely different molecular targets, different pharmacokinetic profiles, different reported behavioral profiles, and different regulatory standings. The comparison illustrates how different the peptide and small-molecule approaches to anxiety-related research can be.
Q.What storage and reconstitution practices apply to Selank?
Lyophilized Selank stored sealed at -20 °C or below away from light is generally considered stable for extended periods. The peptide has no methionine residues to oxidize and no cysteines for disulfide concerns, simplifying storage relative to peptides with those vulnerable residues. Reconstituted material in sterile bacteriostatic water is typically used within several weeks when stored refrigerated. Single-use aliquoting to avoid repeated freeze-thaw cycles is a common practice for research applications. The high proline content of Selank contributes to its overall stability profile.
Q.What is the relationship between Selank and the immune system?
Selank's relationship to the immune system derives from its Tuftsin lineage. Natural Tuftsin is an immunoregulatory peptide released from IgG that acts on phagocytic cells. Selank retains the Tuftsin sequence as its N-terminal core and reportedly retains some of the immunoregulatory activity in research contexts. The compound therefore exhibits a dual-domain activity profile — CNS effects characterized in anxiety-related and broader behavioral research, plus immunoregulatory effects connected to the Tuftsin tradition. The integration of these two activity domains in a single small synthetic peptide is one of the conceptually interesting features of Selank as a research molecule.
Glossary of Terms
- Tuftsin
- Naturally occurring tetrapeptide Thr-Lys-Pro-Arg released from the CH2 domain of the IgG heavy chain by proteolytic cleavage. An immunoregulatory peptide acting on phagocytic cells; the N-terminal starting sequence of Selank.
- Pro-Gly-Pro
- Proline-glycine-proline, the C-terminal three-residue extension of Selank (and of Semax) that confers protease resistance and improves the stability of the molecule against C-terminal proteolytic cleavage.
- Phagocyte / phagocytosis
- Phagocytes are immune cells (monocytes, macrophages, neutrophils) that ingest particulate matter including microorganisms; phagocytosis is the process of ingestion. Tuftsin acts on phagocytic cells to modulate phagocytic function.
- Immunoglobulin G (IgG)
- The major class of antibody in human plasma, composed of two heavy chains and two light chains. The Tuftsin sequence occurs within the CH2 domain of the IgG heavy chain.
- GABAergic
- Pertaining to the neurotransmitter system using gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the CNS. GABA-A and GABA-B receptors mediate the postsynaptic effects of GABA.
- Neuropeptide Y (NPY)
- A 36-amino-acid neuropeptide widely expressed in the CNS with established roles in anxiety, stress responses, feeding regulation, and various other functions. Reported upregulation in response to Selank in some brain regions.
- Anxiolytic
- Pertaining to compounds that reduce anxiety or anxiety-related behavior. Selank exhibits anxiolytic-like behavior in animal-model anxiety paradigms in published research and is registered in Russia for anxiety-related indications.
- Elevated plus maze
- Standard rodent anxiety paradigm in which an animal is placed on a plus-shaped maze with two open arms and two closed arms; willingness to spend time in the open arms is used as an inverse measure of anxiety-like behavior.
- Intranasal
- Route of administration involving delivery to the nasal mucosa. For peptides, the intranasal route bypasses rapid plasma proteolytic degradation and may provide access to the CNS through the olfactory and trigeminal pathways.
- Aminopeptidase
- A protease that cleaves amino acids from the N-terminal end of peptides. Rapid aminopeptidase activity in plasma is one of the major routes of degradation for small unmodified peptides including natural Tuftsin.
- Benzodiazepine
- Class of small-molecule compounds (diazepam, lorazepam, alprazolam, others) that act as positive allosteric modulators at a specific site on the GABA-A receptor. Pharmacologically distinct from Selank's peptide mechanism.
- Shemyakin-Ovchinnikov Institute
- The M. M. Shemyakin and Y. A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, a central site for the development of Russian neuropeptides including Selank and Semax.
Summary
Selank is a synthetic seven-amino-acid peptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed in the Russian neuropeptide research community in the 1990s as a stabilized analog of the natural immunoregulatory tetrapeptide Tuftsin. The first four residues preserve the natural Tuftsin sequence; the C-terminal Pro-Gly-Pro extension confers protease resistance and improves stability relative to the unmodified tetrapeptide. The same stabilization strategy is used in the related Russian neuropeptide Semax, which derives from a different natural peptide starting point.
The published Selank research literature includes effects on anxiety-related behavioral endpoints in animal models, effects on GABAergic neurotransmission and inhibitory signaling, effects on neuropeptide Y expression in brain regions including hippocampus, and effects on immunoregulatory endpoints connected to the Tuftsin lineage. The compound is registered as a pharmaceutical product in the Russian Federation for anxiety-related indications, with supporting clinical-research evidence generated primarily within the Russian regulatory and research ecosystem. It has not been advanced through the conventional pharmaceutical approval pathways in the U.S., EU, or other major international jurisdictions and is available internationally as a research peptide for laboratory and analytical use.
This page treats Selank as an educational subject and a research peptide. It is supplied for laboratory and analytical use only. Nothing in the discussion above constitutes medical advice, describes a treatment for any individual outside the Russian regulatory framework, or makes claims about anxiety, cognitive, or immunoregulatory effects in people who purchase the compound for research. The framing throughout reflects the compound's actual status: a thoughtfully designed stabilized Tuftsin analog with a substantial Russian research literature, registered as a pharmaceutical product in one regulatory jurisdiction, and present internationally as a research peptide of laboratory interest with a continuing role in basic investigation of Tuftsin biology, anxiety-related neuropeptide pharmacology, and immune-CNS interactions.
Scientific References
Selected peer-reviewed and primary-source citations used to inform this educational overview. Inclusion does not imply endorsement of any non-research use of Selank.
- Najjar, V. A., & Nishioka, K. (1970). 'Tuftsin': a natural phagocytosis stimulating peptide. Nature, 228(5272), 672-673.Original identification and naming of Tuftsin, the natural tetrapeptide starting sequence of Selank.
- Kozlovskaya, M. M., Kozlovskii, I. I., Val'dman, E. A., & Seredenin, S. B. (2003). Selank and short peptides of the Tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and Behavioral Physiology, 33(8), 853-860.Russian-tradition characterization of Selank's behavioral and adaptive effects in stress paradigms.
- Kolomin, T., Shadrina, M., Slominsky, P., Limborska, S., & Myasoedov, N. (2013). A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience and Medicine, 4(4), 223-252.Review of the broader Russian neuropeptide design framework including Selank and related stabilized analogs.
- Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology, 7, 31.Characterization of Selank's effects on GABAergic gene expression, one of the proposed mechanistic angles.
- Inozemtseva, L. S., Karpenko, E. A., Dolotov, O. V., Levitskaya, N. G., Kamensky, A. A., Andreeva, L. A., & Grivennikov, I. A. (2007). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences, 421(1), 241-243.Characterization of intranasal Selank's effects on BDNF expression in hippocampus, illustrating the dual neurotrophic and behavioral footprint of the compound.